This is an aggregated industry headline. Read the full story at FiercePharma →
The Oral GLP-1 Tracker: Lilly's Foundayo launch remains 'muted'
Fierce Pharma is launching the weekly Oral GLP-1 Tracker, leveraging analysts' notes and IQVIA data to monitor prescription trends and shifting market shares as Novo Nordisk's Wegovy pill and Eli Lilly's Foundayo vie to become the go-to oral weight-loss solution for millions.
By FiercePharma
· Jul 11, 2026
· via FiercePharma
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineFiercePharma
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFierceBiotech ↗
Hansoh Pharmaceutical's pair of much-hyped ADCs continue to justify partner GSK's decision to make them priori…
The WeekBriefing
The FDA reported no new hires under PDUFA VII or BsUFA III for FY26 through June, with FY25 and FY24 hiring go…
The WeekSTAT News ↗
Sean Kaufman's views on vaccines may put him at odds with Sen. Bill Cassidy during next week's confirmation he…